Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
- Written by PR Newswire
 |
Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration
Poster presentations demonstrate synergistic effects of selectively inhibiting both the alternative and...
